BusinessActinium Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of RecordBy Nasdaq OMXFeb 12, 2018, 12:30 PM UTC
BusinessActinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML PatientsBy Nasdaq OMXFeb 6, 2018, 12:30 PM UTC
BusinessActinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research ProgramsBy Nasdaq OMXJan 8, 2018, 12:31 PM UTC
BusinessActinium Pharmaceuticals Provides Update on Pivotal Phase 3 Trial of Iomab-B: Independent Data Monitoring Committee Recommends SIERRA Trial ContinueBy Nasdaq OMXDec 27, 2017, 2:00 PM UTC
BusinessFDA Grants Orphan Drug Designation to Aptose Biosciences for CG’806 in Acute Myeloid LeukemiaBy Nasdaq OMXDec 26, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual MeetingBy Nasdaq OMXDec 12, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-MBy Nasdaq OMXDec 11, 2017, 9:15 PM UTC
